Current approaches for the management of Parkinson's disease in Chinese hospitals: a cross-sectional survey.

Nevertheless, there was disagreements about which type of PD might benefit more from MAO-B inhibitors, and an extremely significant disparity ( p < 0.0001) on familiarity with the use of disease-modifying/neuroprotective therapy (χ 2 ( N = 711) = 42.9005, p < 0.0001), Rivastigmine for PDD patients (χ 2 ( N = 711) = 20.2759, p < 0.0001), and antipsychotics for psychiatric symptoms managements (χ 2 ( N = 711) = 21.8987, p < 0.0001).

also in 7,787 other papers

Among which, highly significant differences were seen not only in guideline reference, academic exchanging, researching experience, but were not rare in detailed diagnostic methods like Madopar loading test on suspected patients and MRI application.

also in 132,142 other papers